Trial · NCT02115282
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | Arm A (Exemestane, Entinostat) | 3.3 | 95% Confidence Interval 3.1 to 5.3 | months | |
| Progression-free Survival (PFS) | Arm B (Exemestane, Placebo) | 3.1 | 95% Confidence Interval 3.0 to 3.3 | months | |
| Overall Survival (OS) | Arm A (Exemestane, Entinostat) | 23.4 | 95% Confidence Interval 21.2 to 25.6 | months | |
| Overall Survival (OS) | Arm B (Exemestane, Placebo) | 21.7 | 95% Confidence Interval 19.3 to 27.1 | months | |
| Objective Response Rate (ORR) | Arm A (Exemestane, Entinostat) | 4.6 | 95% Confidence Interval 2.5 to 7.6 | percentage of participants | |
| Objective Response Rate (ORR) | Arm B (Exemestane, Placebo) | 4.3 | 95% Confidence Interval 2.3 to 7.2 | percentage of participants | |
| Time-to-treatment Deterioration (TTD) | Arm A (Exemestane, Entinostat) | 2.9 | 95% Confidence Interval 2.8 to 3.1 | months | |
| Time-to-treatment Deterioration (TTD) | Arm B (Exemestane, Placebo) | 2.9 | 95% Confidence Interval 2.8 to 3.0 | months | |
| Lysine Acetylation Change in CD45 Blood Mononuclear Cells Between C1D1 and C1D15 and PFS in Patients on Arm A | Arm A (Exemestane, Entinostat)- Lysine Acetylation Change>=1.5 Fold | 2.8 | 95% Confidence Interval 2.5 to 5.1 | months | |
| Lysine Acetylation Change in CD45 Blood Mononuclear Cells Between C1D1 and C1D15 and PFS in Patients on Arm A | Arm A (Exemestane, Entinostat)- Lysine Acetylation Change<1.5 Fold | 2.7 | 95% Confidence Interval 2.5 to 5.2 | months | |
| Patient-reported Health-related Quality of Life | Arm A (Exemestane, Entinostat) | 20.5 | Standard Deviation 5.0 | units on a scale | |
| Patient-reported Health-related Quality of Life | Arm B (Exemestane, Placebo) | 20.9 | Standard Deviation 4.7 | units on a scale | |
| Patient-reported Diarrhea | Arm A (Exemestane, Entinostat) | 38.8 | Standard Deviation 7.2 | units on a scale | |
| Patient-reported Diarrhea | Arm B (Exemestane, Placebo) | 41.5 | Standard Deviation 4.3 | units on a scale | |
| Patient-reported Fatigue | Arm A (Exemestane, Entinostat) | 55.5 | Standard Deviation 8.2 | T-score | |
| Patient-reported Fatigue | Arm B (Exemestane, Placebo) | 54.1 | Standard Deviation 8.9 | T-score | |
| Patient-reported Nausea and Anorexia | Arm A (Exemestane, Entinostat) | 35.8 | Standard Deviation 7.8 | units on a scale | |
| Patient-reported Nausea and Anorexia | Arm B (Exemestane, Placebo) | 37.0 | Standard Deviation 7.9 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02115282/results